Today: March 26, 2017, 3:05 pm

New Market Research Report: Primary Dysmenorrhea - Pipeline Review, H1 2014

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research 2014-03-09 12:40:59
Global Markets Direct's, 'Primary Dysmenorrhea - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Primary Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- ..

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

* A snapshot of the global therapeutic scenario for Primary Dysmenorrhea.
* A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Primary Dysmenorrhea pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Merck & Co., Inc., PDC Biotech GmbH, Jiangsu Kanion Pharmaceutical Co., Ltd.

Partial Table of Contents:

Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Primary Dysmenorrhea Overview
Therapeutics Development
Pipeline Products for Primary Dysmenorrhea - Overview
Pipeline Products for Primary Dysmenorrhea - Comparative Analysis
Primary Dysmenorrhea - Therapeutics under Development by Companies
Primary Dysmenorrhea - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Primary Dysmenorrhea - Products under Development by Companies
Primary Dysmenorrhea - Companies Involved in Therapeutics Development
Merck & Co., Inc.
PDC Biotech GmbH
Jiangsu Kanion Pharmaceutical Co., Ltd.
Primary Dysmenorrhea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Drug Profiles
KYG-0395 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etonogestrel Vaginal Ring - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptidometics - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC-41 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primary Dysmenorrhea - Recent Pipeline Updates
Primary Dysmenorrhea - Dormant Projects
Primary Dysmenorrhea - Product Development Milestones
Featured News & Press Releases
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor
Nov 01, 2012: Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related To Vioxx
Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007.
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007.
Secondary Research
Primary Research
Expert Panel Validation
Contact Us

List of Tables
Number of Products under Development for Primary Dysmenorrhea, H1 2014
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Primary Dysmenorrhea - Pipeline by Merck & Co., Inc., H1 2014
Primary Dysmenorrhea - Pipeline by PDC Biotech GmbH, H1 2014
Primary Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2014
Assessment by Monotherapy Products, H1 2014

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Press Information

Published by
Bill Thompson

# 946 Words
Related Articles
More From Health
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo [..]
PromarkerD Predictive Diagnostics for DKD to Roll-out [..]
PERTH, AUSTRALIA, Mar 22, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader [..]
Do Prostalgene Drops Help To Restore Prostate [..]
Prostate enlargement is among the most common health problems for men over 50. With age the incidence of this condition [..]
Is OnycoSolve Spray The Key To Obliterating [..]
Toenail fungus is an undesirable but stubborn infection that comes with sweating, itching, cracking and scaling of the feet, inflammations, [..]
New Research reveals Asia poised as Preferred [..]
SYDNEY, Mar 10, 2017 - (ACN Newswire) - Frost & Sullivan has released its latest white paper, 'Asia: Preferred Destination for [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.